{"id":"kremezin-granule","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Kremezin granule","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:44:46.258043+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:45:00.688233+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:44:53.045979+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kremezin granule","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:44:53.456190+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL564/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:44:54.181438+00:00"}},"_dailymed":null,"aiSummary":"Kremezin granule, marketed by Daewon Pharmaceutical Co., Ltd., holds a significant position in its therapeutic segment. The key composition patent for Kremezin is set to expire in 2028, providing a clear period of market exclusivity. However, the lack of detailed revenue data and primary trial results poses a risk in assessing its long-term market sustainability and competitive edge.","_scrapedAt":"2026-03-27T23:51:20.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:45:00.688323+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02681952","phase":"PHASE4","title":"A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2015-12","conditions":"Chronic Renal Failure","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL564"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Kremezin granule","genericName":"Kremezin granule","companyName":"Daewon Pharmaceutical Co., Ltd.","companyId":"daewon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:45:00.688323+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}